Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 12, 2026 · Other material event · Investor press release · Financial statements
MBX Biosciences, Inc.
44
Other material event
Jun 12, 2026
| ItemItem | Disclosure |
|---|---|
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
MBX Biosciences, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through s…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
MBX Biosciences, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
